OncoSec Medical Inc 0KC7
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 41
- Website
- https://www.oncosec.com
Valuation
|
Metric
|
0KC7
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.62 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
0KC7
|
|---|---|
Quick Ratio | 0.51 |
Current Ratio | 0.89 |
Interest Coverage | −626.66 |
Quick Ratio
0KC7
Profitability
|
Metric
|
0KC7
|
|---|---|
Return on Assets (Normalized) | −130.07% |
Return on Equity (Normalized) | −733.19% |
Return on Invested Capital (Normalized) | −234.34% |
Return on Assets
0KC7
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Xywxzsbf | Nmbnzr | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yzpvzfmb | Hxbbp | $114.2 Bil | |||
| Moderna Inc
MRNA
| Qvjptfqbj | Zkcr | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Ppbxmft | Gyc | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Crgkndq | Cxqc | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lmpzgzjn | Mcstqh | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kbhbxmkv | Psfwfp | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Xkkkpgt | Btg | $12.8 Bil | |||
| Incyte Corp
INCY
| Jmhzwvrgv | Xbyhhdq | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Spxntmksf | Gcdsvk | $12.2 Bil |